Epimerase Pathways for R-Benzylisoquinoline Alkaloid Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing benzylisoquinoline alkaloids in host cells are inefficient and do not effectively convert (S)-1-benzylisoquinoline alkaloids to (R)-1-benzylisoquinoline alkaloids, limiting the diversity and yield of these compounds.
Innovation Solution
Engineered host cells with enhanced tyrosine hydroxylase activity and specific epimerases, such as those with SEQ ID NOs: 1-15, are used to epimerize (S)-1-benzylisoquinoline alkaloids to (R)-1-benzylisoquinoline alkaloids, and produce diverse alkaloid products through epimerization reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing methods are used for producing benzylisoquinoline alkaloids in host cells, then the production process is simple, but the efficiency and yield are low
Solution Approach 1:
The patent divides the alkaloid production pathway into distinct enzymatic steps, with each step catalyzed by a specific engineered enzyme. The pathway includes tyrosine hydroxylase for L-DOPA synthesis, norcoclaurine synthase for norcoclaurine formation, reticuline synthase for reticuline production, and epimerases for stereoisomer conversion. This segmentation allows optimization of each step independently to improve overall productivity.
Solution Approach 2:
The patent employs multiple parameter changes including enzyme engineering to alter catalytic efficiency, codon optimization to improve gene expression levels, and pathway balancing to optimize substrate availability. These parameter changes collectively enhance production efficiency while maintaining manageable process complexity.
2Manufacturing precision
If (S)-1-benzylisoquinoline alkaloids are produced through existing methods, then the stereochemistry is controlled, but the conversion to (R)-1-benzylisoquinoline alkaloids is ineffective
Solution Approach 1:
The patent introduces epimerase enzymes as intermediary catalysts to facilitate the stereospecific conversion between (S)- and (R)-1-benzylisoquinoline alkaloids. These epimerases act as mediators that selectively invert the stereochemistry at specific positions while maintaining control over the epimerization process, thereby achieving both stereochemical precision and effective conversion.
3Productivity
If enzyme activity is increased to overcome substrate and product inhibition, then the production yield improves, but the enzyme stability may decrease
Solution Approach 1:
The patent employs preliminary enzyme engineering and pathway optimization before production scaling. Enzymes are pre-optimized for stability through directed evolution or rational design, and the metabolic pathway is pre-balanced to prevent excessive accumulation of substrates or products that could cause inhibition. This preliminary preparation ensures both high productivity and enzyme stability during production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered host cells significantly increase the production and diversity of benzylisoquinoline alkaloids, including (R)-reticuline, by overcoming substrate and product inhibition, and enhancing enzyme activity.
Implementation Method 1
Engineered host cells with enhanced tyrosine hydroxylase activity
Implementation Method 2
specific epimerases, such as those with SEQ ID NOs: 1-15, are used to epimerize (S)-1-benzylisoquinoline alkaloids to (R)-1-benzylisoquinoline alkaloids
Data Source
AI summary
A method of epimerizing an (S)-1-benzylisoquinoline alkaloid to an (R)-1-benzylisoquinoline alkaloid is provided. The method comprises contacting the (S)-1-benzylisoquinoline alkaloid with at least one enzyme. Contacting the (S)-1-benzylisoquinoline alkaloid with the at least one enzyme converts the (S)-1-benzylisoquinoline alkaloid to an (R)-1-benzylisoquinoline alkaloid.